# Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Canonical URL: https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2026
Ticker: NBIX
Company: Neurocrine Biosciences
Source: Neurocrine Biosciences
Published: 2026-06-25 13:46 EST
Original Source URL: https://neurocrine.gcs-web.com
## Summary

Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at

## Article Body
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at
## Recent Company News
- 2026-07-01 20:05 EST — [Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-initiates-phase-2-study-of-crinecerfont-in-pediatric-pati-8fe2e2b9) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-first-retrospective-case-series-of-crenessityr-crinecerfont-in-patients-with-classic-congenital-adrenal-hyperplasia-due-to-11-hydroxylase-deficiency-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period](https://biopharmsignal.com/news/NBIX/soleno-therapeutics-presents-new-vykatr-xr-diazoxide-choline-data-at-endo-2026-demonstrating-meaningful-and-durable-improvements-in-hyperphagia-and-behavioral-symptoms-in-prader-willi-syndrome-following-randomized-withdrawal-period) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-demonstrating-improved-growth-measures-in-pediatric-patients-with-classic-congenital-adrenal-hyperplasia-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2026) — Source: Neurocrine Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)